The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Challenges and Opportunities of Nanomedicines in Clinical Translation
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One challenge in clinical translation is the long-term fate of nanoparticles. Biodegradation rates, excretion pathways, and possible interactions with other medications must be fully understood [73].”
From Advances in green-synthesized magnetic nanoparticles for targeted cancer therapy: mechanisms, applications, and future perspectives (2026) · cites this paper as [73]
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Self-citation
Research works printed but not linked: 23
- J Wolfram, 2019, Clinical cancer nanomedicine, Nano Today, 25, 85, 10.1016/j.nantod.2019.02.005 · DOI
- J Shi, 2017, Cancer nanomedicine: Progress, challenges and opportunities, Nat Rev Cancer, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
- Y Min, 2015, Clinical translation of nanomedicine, Chem Rev, 115, 11147, 10.1021/acs.chemrev.5b00116 · DOI
- DX Sun, 2020, What went wrong with anticancer nanomedicine design and how to make it right, ACS Nano, 14, 12281, 10.1021/acsnano.9b09713 · DOI
- M Hay, 2014, Clinical development success rates for investigational drugs, Nat Biotechnol, 32, 40, 10.1038/nbt.2786 · DOI · Paper page
- A Wicki, 2015, Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications, J Control Release, 200, 138, 10.1016/j.jconrel.2014.12.030 · DOI
- C Zhang, 2020, Progress, challenges, and future of nanomedicine, Nano Today, 35, 10.1016/j.nantod.2020.101008 · DOI
- YH Bae, 2020, Advanced drug delivery 2020 and beyond: Perspectives on the future, Adv Drug Del Rev, 158, 4, 10.1016/j.addr.2020.06.018 · DOI
- Y Ding, 2020, Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy, Nano Today, 35, 10.1016/j.nantod.2020.100970 · DOI
- J Bourquin, 2018, Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials, Adv Mater, 30, 10.1002/adma.201704307 · DOI
- J Ding, 2019, Engineered nanomedicines with enhanced tumor penetration, Nano Today, 29, 10.1016/j.nantod.2019.100800 · DOI
- L Wei, 2021, Sequentially stimuli-responsive anticancer nanomedicines, Nanomedicine, 16, 261, 10.2217/nnm-2021-0019 · DOI
- C Li, 2020, Innovative Irinotecan-loaded nanomicelles will enter Phase I clinical trial in 2021, The Innovation, 1
- Y Zhao, 2019, Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice, Nano Lett, 19, 674, 10.1021/acs.nanolett.8b03644 · DOI
- Y Zhao, 2020, Neuroprotective nanoscavenger induces coaggregation of β-amyloid and facilitates its clearance in Alzheimer’s disease brain, CCS Chem, 2316
- DJ Irvine, 2020, Enhancing cancer immunotherapy with nanomedicine, Nat Rev Immunol, 20, 321, 10.1038/s41577-019-0269-6 · DOI
- AE Nel, 2009, Understanding biophysicochemical interactions at the nano-bio interface, Nat Mater, 8, 543, 10.1038/nmat2442 · DOI · Paper page
- S Li, 2020, Oral delivery of bacteria: Basic principles and biomedical applications, J Control Release, 10, 801, 10.1016/j.jconrel.2020.09.011 · DOI
- H Hu, 2021, Flash technology-based self-assembly in nanoformulation: Fabrication to biomedical applications, Mater Today, 42, 99, 10.1016/j.mattod.2020.08.019 · DOI
- J Xu, 2013, Future of the particle replication in nonwetting templates (PRINT) technology, Angew Chem Int Ed, 52, 6580, 10.1002/anie.201209145 · DOI · Paper page
- JM Lim, 2014, Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer, ACS Nano, 8, 6056, 10.1021/nn501371n · DOI
- Fong, 2012, Building bridges: Leveraging interdisciplinary collaborations in the development of biomaterials to meet clinical needs, Adv Mater, 24, 4995, 10.1002/adma.201201762 · DOI
- TC Roberts, 2020, Advances in oligonucleotide drug delivery, Nat Rev Drug Discov, 19, 673, 10.1038/s41573-020-0075-7 · DOI
Cited by
Sorted by citations
El-khawaga, A. M., Youssef, O. I., El-dydamoni, O. A., Ragab, W. M., & Mohammed, R. A. E. (2026) · European Journal of Medical Research · doi:10.1186/s40001-025-03804-9 · Cited by 14
Metadata
- Authors
- Zheng, C., Li, M., & Ding, J.
- Venue
- BIO Integration
- Publisher
- Compuscript, Ltd.
- Published
- 2021
- Volume
- 2
- Issue
- 2
- ISSN
- 2712-0074
- 2712-0082
- Cited by
- 194
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review